Upcoming Webinars
“ADMET Predictor 10.4 (APX.4) Software Release”
Wednesday, May 18, 2022
5 AM CEST (Paris) / 8 AM PT (Los Angeles) / 11 AM ET (New York)
The webinar will explore the new ADMET Predictor® 10.4 (APX.4) flagship machine learning platform for ADMET modeling, with extended capabilities for data analysis, metabolism prediction, and AI-driven drug design.
The following topics will be covered:
• New functionality for generating high-quality 3D conformers
• HTPK Module enhancements, including support for mouse physiology
• Updated Ames mutagenicity models
• Major improvements to the REST API, including Linux support
Register now to see and hear the latest advancements in ADMET Predictor®!
Presenters:
Dr. David Miller, Vice President, Cheminformatics, Simulations Plus
Dr. Eric Jamois, Director, Business Development, Simulations Plus
“Using PBPK modeling to assess the impact of diseases on oral drug absorption: a tale of 2 drugs”
Wednesday, June 29, 2022
5 AM CEST (Paris) / 8 AM PT (Los Angeles) / 11 AM ET (New York)
Randomized clinical trial is the most effective way to determine whether a cause-and-effect relationship exists between an intervention and a predefined clinical outcome. Much attention has been paid to the internal validity of a clinical trial, i.e. the extent to which the design and conduct of a trial eliminates the possibility of bias. In this webinar, we will go over two case studies leveraging IVIVE-PBPK modeling to prospect the impact of HIV and cystic fibrosis on the oral absorption of two broadly prescribed BCS 2 drugs.
Presenter:
Dr. Rodrigo Cristofoletti
Assistant Professor, Center for Pharmacometrics & Systems Pharmacology, Dept. of Pharmaceutics
University of Florida
“Predicting pharmacokinetics of multisource acyclovir oral products through Physiologically Based Biopharmaceutics Modeling”
Wednesday, July 13, 2022
5 AM CEST (Paris) / 8 AM PT (Los Angeles) / 11 AM ET (New York)
Highly variable disposition after oral ingestion of acyclovir has been reported, although little is known regarding the underlying mechanisms. Different studies using the same reference product (Zovirax ®) showed that Cmax and AUC were respectively 44 and 35% lower in Saudi Arabians than Europeans, consistent with higher frequencies of reduced-activity polymorphs of the organic cation transporter (OCT1) in Europeans. This webinar will explore this study in depth.
Presenters:
Dr. Peter Langguth, University Professor at Johannes Gutenberg University Mainz
Dr. Mauricio A. Garcia, PhD student/Research Assistant, Johannes Gutenberg University Mainz
Watch Past Webinars
Active Learning in a Pandemic: Teaching Biopharmaceutics with GastroPlus®
This webinar will showcase the use of GastroPlus® for a pharmacy course.
Stream
Membrane Plus v3 Release Webinar
Learn about new, improved, and enhanced features to drive advances to in vitro-in vivo extrapolation (IVIVE) for permeability, hepatocyte, skin penetration, and release assay systems.
Stream
Applying Mechanistic Modeling to Predict Food Effects on Drugs: Approaches and Special Considerations
The focus of this webinar will be to discuss how physiological differences between fasted and fed states have been incorporated into mechanistic absorption (MAM) and physiologically based pharmacokinetic (PBPK) models to predict positive and negative food effects.
Stream Download
Exploratory Study on Lercanidipine Hydrochloride Polymorphism: pH-Dependent Solubility Behavior
Based on the recent publication from AAPS PharmSci Tech, this 60-minute webinar will showcase an example of the use of GastroPlus® to assess the risk and pharmacokinetic relevance of different solubility and particle size between crystal forms of a poorly water-soluble antihypertensive drug, for diverse physiological conditions.
Stream Download
